F. Hoffmann-La Roche Ltd: Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older
F. Hoffmann-La Roche Ltd: Roche receives positive CHMP opinion for Evrysdi, the first and only at home spinal muscular atrophy (SMA) treatment with proven efficacy in adults, children and infants two months and older More than 2,500 patients now treated with Evrysdi in clinical trial, compassionate use and real-world settings Evrysdi is approved in seven countries, submitted in 30 more Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Evrys...
Source: finanznachrichten.de